Alnylam Pharmaceuticals
ALNY
521 hedge funds and large institutions have $29.1B invested in Alnylam Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 88 funds opening new positions, 194 increasing their positions, 166 reducing their positions, and 58 closing their positions.
70% more capital invested
Capital invested by funds: $17.2B → $29.1B (+$12B)
52% more first-time investments, than exits
New positions opened: 88 | Existing positions closed: 58
17% more call options, than puts
Call options by funds: $703M | Put options by funds: $600M
17% more repeat investments, than reductions
Existing positions increased: 194 | Existing positions reduced: 166
5% more funds holding
Funds holding: 498 → 521 (+23)
3.63% more ownership
Funds ownership: 91.15% → 94.78% (+3.6%)
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$347M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$344M |
| 3 |
OAG
Orbis Allan Gray
Hamilton,
Bermuda
|
+$114M |
| 4 |
BlackRock
New York
|
+$82.5M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$81.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$158M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$93.3M |
| 3 |
Squarepoint
New York
|
-$76M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$52.5M |
| 5 |
VPC
Vestal Point Capital
New York
|
-$52.3M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SC
576
SouthState Corp
Winter Haven,
Florida
| – | -$897 | -6 | Closed |
|
|
DIP
577
DT Investment Partners
Chadds Ford,
Pennsylvania
| – | -$748 | -5 | Closed |
|
|
FGAM
578
Financial Gravity Asset Management
Lakeway,
Texas
| – | -$830 | -5 | Closed |
|
579
Kayne Anderson Rudnick Investment Management
Los Angeles,
California
| – | -$598 | -4 | Closed |
|
|
AWM
580
Abound Wealth Management
Franklin,
Tennessee
| – | -$449 | -3 | Closed |
|
|
CFO
581
CVA Family Office
Denver,
Colorado
| – | -$448 | -3 | Closed |
|
ALNY Hedge Fund Activity: Q2 2024 in Review
521 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q2 2024, worth a combined $29.1B — up 70% from $17.2B a quarter earlier.
Buyers outnumbered sellers: 88 funds opened new ALNY positions and 58 closed out — a net gain of 30 holders — while 194 added to existing stakes and 166 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $347M. The largest seller was Wellington Management Group, cutting an estimated $158M.
- 521 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q2 2024, up from 498 in Q1 2024.
- Funds reported $29.1B of Alnylam Pharmaceuticals stock for Q2 2024, up 70% quarter-over-quarter.
- 88 funds opened new Alnylam Pharmaceuticals positions in Q2 2024 and 58 closed out, a net change of +30 holders.
- The largest Alnylam Pharmaceuticals buyer in Q2 2024 was Fidelity Investments, an estimated $347M added.
- The largest Alnylam Pharmaceuticals seller in Q2 2024 was Wellington Management Group, an estimated $158M sold.
Based on aggregated 13F filings for Q2 2024.